Lunch Symposium (I)
Targeted Therapies In Neuroendocrine Tumors
12:20 - 13:00, L & B Cafe (醫圖咖啡廳)
Abstract - Targeted therapies in neuroendocrine tumors
Neuroendocrine tumors are a group of heterogeneous malignancies arising from neuroendocrine cells throughout the body. Data from population-based registries indicate that 51% of neuroendocrine tumors arise from the gastrointestinal (GI) tract, 27% from the lungs, and 6% from the pancreas. Clinically, neuroendocrine tumors are regarded as functional if they are associated with symptoms of hormonal hypersecretion, or non-functional if they are not associated with these symptoms. Although carcinoid syndrome is classically associated with metastatic, well-differentiated neuroendocrine tumors of the small intestine, an analysis of National Comprehensive Cancer Centre database showed that most (74%) neuroendocrine tumors are nonfunctional.
Advanced neuroendocrine tumors are incurable in nearly all cases. The somatostatin analogue, approved for control of hormonal syndrome, has been shown to delay disease progression in patients with neuroendocrine tumors. Targeted therapies such as everolimus and sunitinib are approved for advanced pancreatic neuroendocrine tumors.
In addition, everolimus showed robust anti-tumor activity with acceptable tolerability across a broad range of neuroendocrine tumors, including those arising from the GI tract and lung (RADIANT 4 study). Other treatment strategies, including chemotherapy (E2211 trial) and peptide receptor radiotherapy (NETTLER study) are also approved for advanced well differentiated NETs.
Recently, several potential targeted therapies were developed in well differentiated NETs and showed promising results in phase 2 clinical trials. NETs have emerged due to an improved understanding of the molecular mechanisms responsible for tumor development and progression.